American Oncology Network | Hematology Oncology Clinic

Research site

(Unclaimed)

Location

8585 Picardy Avenue, Baton Rouge, Louisiana, United States of America

Site insights

Top conditions

Top treatments

Paclitaxel

Bevacizumab

LOXO-305

Atezolizumab

ZEN003694

Sacituzumab

SAR439859

Ibrutinib

Leucovorin

Abiraterone Acetate

Parent organization

This site is a part of American Oncology Network

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

18 of 29 total trials

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Versus Placebo Combined With AA-P as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer

To evaluate whether Fuzuloparib plus AA-P is superior to placebo plus AA-P as first-line treatment by assessment of radiographic progression-free sur...

Enrolling

Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Drug: Fuzuloparib Placebo， Abiraterone acetate and Prednisone

Drug: Fuzuloparib , Abiraterone acetate and Prednisone

A Phase III, Open-Label Study of Maintenance Lurbinectedin in Combination With Atezolizumab Compared With Atezolizumab in Participants With Extensive-Stage Small-Cell Lung Cancer (IMforte)

Study GO43104 is a Phase III, randomized, open-label, multicenter study of lurbinectedin in combination with atezolizumab compared with atezolizumab...

Active, not recruiting

Small-Cell Lung Cancer

Drug: Atezolizumab

Drug: Lurbinectedin

A Study Evaluating Atezolizumab and Bevacizumab, With or Without Tiragolumab, in Participants With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma (IMbrave152) (SKYSCRAPER-14)

The purpose of this study is to assess the efficacy and safety of tiragolumab, an anti-TIGIT monoclonal antibody, when administered in combination wi...

Enrolling

Carcinoma, Hepatocellular

Drug: Tiragolumab

Other: Placebo

A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun)

This study will evaluate the efficacy, safety, and pharmacokinetics of mosunetuzumab subcutaneous (SC) formulation in participants with selected B-ce...

Active, not recruiting

Non-Hodgkin Lymphoma

Drug: Mosunetuzumab (Cohorts A-C)

Drug: Mosunetuzumab (Cohorts D-E)

A Study of Combination of Selinexor, Pomalidomide, and Dexamethasone (SPd) Versus Elotuzumab, Pomalidomide, and Dexamethasone (EloPd) in Subject With Previously Treated Multiple Myeloma

This phase 3 randomized, open-label multicenter trial will compare the efficacy, safety and the impact on health-related quality of life (HR-QoL) of...

Enrolling

Multiple Myeloma

Drug: Selinexor

Drug: Elotuzumab

A Study of Efficacy and Safety of Fruquintinib (HMPL-013) in Participants With Metastatic Colorectal Cancer (FRESCO-2)

This is a global, randomized, double-blind, placebo-controlled, multicenter phase 3 clinical trial to compare the efficacy and safety of fruquintinib...

Active, not recruiting

Metastatic Colorectal Cancer

Metastatic Colon Cancer

Drug: Fruquintinib

Drug: Placebo

A Study of Navicixizumab Monotherapy or in Combination in Patients With Select Advanced Solid Tumors

This is a study of navicixizumab monotherapy or in combination with paclitaxel or irinotecan in patients with advanced cancer. Patients will be enrol...

Enrolling

Gastric Cancer

Ovarian Cancer

Biological: navicixizumab+irinotecan

Biological: navicixizumab monotherapy

A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) (BRUIN-CLL-314)

The purpose of this study is to compare the efficacy and safety of pirtobruitinib (LOXO-305) to ibrutinib in participants with CLL/SLL. Participants...

Active, not recruiting

Leukemia, B-cell

Small Lymphocytic Lymphoma

Drug: Pirtobrutinib

Drug: Ibrutinib

A Study to Assess the Effectiveness and Safety of Irinotecan Liposome Injection, 5-fluorouracil/Leucovorin Plus Oxaliplatin in Patients Not Previously Treated for Metastatic Pancreatic Cancer, Compared to Nab-paclitaxel+Gemcitabine Treatment (NAPOLI 3)

The purpose of this study is to look at the efficacy and safety of Irinotecan liposome injection in combination with other approved drugs used for ca...

Active, not recruiting

Metastatic Adenocarcinoma of the Pancreas

Drug: Leucovorin

Drug: Gemcitabine

Combination Study of RMC-4630 and Sotorasib for NSCLC Subjects With KRASG12C Mutation After Failure of Prior Standard Therapies

The purpose of this study is to evaluate the antitumor effects of sotorasib and RMC-4630 in subjects with KRASG12C mutant NSCLC

Active, not recruiting

Non-Small Cell Lung Cancer

Drug: RMC-4630

Drug: Sotorasib

Evaluation of Lasofoxifene Combined with Abemaciclib Compared with Fulvestrant Combined with Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer with an ESR1 Mutation (ELAINEIII)

The goal of this clinical trial is to assess the efficacy, safety and tolerability of the combination of lasofoxifene and abemaciclib compared to ful...

Enrolling

Metastatic Breast Cancer

Drug: Lasofoxifene in combination with abemaciclib

Drug: Fulvestrant in combination with abemaciclib

High Dose IL 2 and Entinostat in RCC

This is a multicenter, randomized, open label study of high dose interleukin 2 vs high dose interleukin 2 plus entinostat in clear cell RCC patients...

Active, not recruiting

Renal Cell Carcinoma

Drug: Entinostat

Drug: Interleukin-2

Phase 2 Study of Amcenestrant (SAR439859) Versus Physician's Choice in Locally Advanced or Metastatic ER-positive Breast Cancer (AMEERA-3)

Primary Objective:To determine whether amcenestrant per overall survival (os) improves progression free survival (PFS) when compared with an endocrin...

Active, not recruiting

Breast Cancer Metastatic

Drug: Tamoxifen

Drug: Anastrozole

Phase 2 Study of DKN-01 in Colorectal Cancer (DeFianCe)

This is a Phase 2 randomized, open-label, two-part, multicenter study with a safety run-in to evaluate efficacy and safety of DKN-01 plus FOLFIRI/FOL...

Active, not recruiting

Colorectal Adenocarcinoma

Colo-rectal Cancer

Drug: Bevacizumab

Drug: FOLFOX

Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL) (BRUIN-MCL-321)

This is a study for participants with a type of blood cancer called mantle cell lymphoma (MCL). The main purpose is to compare pirtobrutinib (LOXO-30...

Active, not recruiting

Lymphoma, Mantle-Cell

Drug: Ibrutinib

Drug: Pirtobrutinib

Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer Who Have Received Endocrine Therapy (ASCENT-07)

The goal of this clinical study is to see if sacituzumab govitecan-hziy (SG) can improve life spans of people with HR+/HER2- metastatic breast cancer...

Active, not recruiting

Locally Advanced or Unresectable Metastatic Breast Cancer

Stage IV Breast Cancer

Drug: Paclitaxel

Drug: Capecitabine

Study of Safety, Pharmacokinetics, and Antitumor Activity of BGB-3245 in Participants With Advanced or Refractory Tumors

The purpose of this study is to evaluate the safety, tolerability, and antitumor activity of BGB-3245 in participants with advanced or refractory sol...

Enrolling

Solid Tumor

B-Raf Mutation-Related Tumors

Drug: BGB-3245

ZEN003694 and Enzalutamide Versus Enzalutamide Monotherapy in Metastatic Castration-Resistant Prostate Cancer

This is an open-label, randomized, Phase 2b study of ZEN003694 in combination with enzalutamide vs. enzalutamide monotherapy in patients with mCRPC w...

Enrolling

Metastatic Castration-Resistant Prostate Cancer

Drug: ZEN003694

Drug: Enzalutamide